Jonathan Provoost - 10 Jan 2025 Form 4 Insider Report for AMARIN CORP PLC\UK (AMRN)

Reporting relationship: EVP, Chief Legal Officer
Issuer ticker: AMRN
Reported as of: 10 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jan 2025, 17:00:06 UTC
Prior SEC filing: 05 Dec 2023
Next SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Provoost

Key filing fact

Jonathan Provoost filed Form 4 for AMARIN CORP PLC\UK (AMRN) on 10 Jan 2025.

Key facts

This page summarizes Jonathan Provoost's Form 4 filing for AMARIN CORP PLC\UK (AMRN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jan 2025, 17:00.

Change

Previous filing in this sequence was filed on 05 Dec 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMRN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +663,878
Change %
Price: $0.000000
Shares after: 663,878
Date: 10 Jan 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 663,878
Exercise price: $0.6200
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Grant price is set at the higher of (1) our nominal par value of 50 pence per share, or as converted on date of grant of $0.62 per share, for which our Plan dictates under United Kingdom law, or (2) fair market value of stock price on the NASDAQ at close of business day.

Footnote F2

On January 10, 2025, the Reporting Person was granted an option to purchase 663,878 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over eighteen months, with 50% to vest on the first anniversary of the grant date and the remaining balance to vest eighteen months after grant date.

Footnote F3

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.